UnknownPhase 2NCT04705129

Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCL

Studying Epstein-Barr virus-positive diffuse large B-cell lymphoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Ruijin Hospital
Principal Investigator
Weili Zhao, PhD, MD
Ruijin Hospital
Intervention
Zanubrutinib(drug)
Enrollment
40 enrolled
Eligibility
18-80 years · All sexes
Timeline
20212024

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04705129 on ClinicalTrials.gov

Other trials for Epstein-Barr virus-positive diffuse large B-cell lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Epstein-Barr virus-positive diffuse large B-cell lymphoma

← Back to all trials